NOVO NORDISK A/S Read the full release with references
Milan, Italy, 10 November 2015 - New findings from a health economics and outcomes research (HEOR) analysis demonstrated that Victoza® (liraglutide) 1.2 mg is cost-effective for the treatment of type 2 diabetes in the UK market when compared to lixisenatide and is cost-saving compared to exenatide.1 Findings were presented today at the 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in Milan, Italy.
Further information| Media: | ||
| Katrine Sperling | +45 4442 6718 | krsp@novonordisk.com |
| Åsa Josefsson | +45 30797708 | aajf@novonordisk.com |
Investors: |
1. Ashley D, Vega G, Hunt B, et al. Evaluating the cost-effectiveness of GLP-1 receptor agonists for the treatment of type 2 diabetes in the UK. PDB 54: B20. 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Milan, Italy, 7-11 November 2015.
|
distributed by
|
